New vaccine technology targeting enterotoxigenic Escherichia coli shows promise in preventing severe diarrheal illnesses, following decades of research at the University of Bergen and now licensed to Valneva.
A significant milestone has been reached in the development of a vaccine against enterotoxigenic Escherichia coli (ETEC), a leading cause of severe digestive illnesses worldwide. After decades of research, scientists have developed a novel vaccine technology that has now been licensed to the French vaccine manufacturer Valneva for further advancement.
ETEC is responsible for millions of diarrheal illnesses each year, particularly affecting children in low- and middle-income countries. Despite extensive research efforts, there has yet to be a broadly effective vaccine to prevent infections caused by this bacterium, according to the latest findings.
The research, led by scientists at the University of Bergen and the Norwegian Research Center (NORCE), focused on a specific toxin produced by ETEC that has long posed challenges in vaccine development. This breakthrough could pave the way for a vaccine that protects vulnerable populations from severe diarrheal diseases.
Dr. James Fleckenstein, a professor of medicine and molecular microbiology at Washington University School of Medicine in St. Louis, commented on the significance of the findings. Although he was not involved in the research, he noted that the approach appears promising. “We still have a lot of work to do to translate these findings to an actual vaccine,” he said. “But the proteins elicit strong antibody responses that seem to offer protection against diarrheal illness after the first infection in children in developing countries.”
If the vaccine progresses to clinical use, researchers hope it will significantly reduce the incidence of severe diarrheal diseases caused by ETEC among children. In the meantime, Dr. Fleckenstein advises travelers to take precautions to minimize their risk of diarrheal illnesses. He recommends avoiding high-risk foods, particularly meals from street vendors in areas with poor sanitation, drinking bottled water in higher-risk regions, and maintaining good hand hygiene.
Additionally, he pointed out that vaccines are available to protect against typhoid fever, and travelers should consult their physicians before embarking on international trips.
While the licensing agreement allows Valneva to advance the research, the technology is still in development and has not yet been tested as an approved vaccine for public use. Further laboratory studies, clinical trials, and regulatory reviews will be necessary before the vaccine can be made available to the public.
As research continues, the hope remains that this innovative vaccine technology will ultimately provide a much-needed solution to combat one of the most prevalent causes of diarrheal illness worldwide, according to Fox News.